These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 35092381

  • 21. Somatic mutations and immune checkpoint biomarkers.
    Parris BA, Shaw E, Pang B, Soong R, Fong K, Soo RA.
    Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
    [Abstract] [Full Text] [Related]

  • 22. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L, Lin Z, Li N, Jiang J, Lu C, Du S, Zhang J, Wang Y, Chen J, Gong P.
    Zhongguo Fei Ai Za Zhi; 2021 Sep 20; 24(9):623-631. PubMed ID: 34455737
    [Abstract] [Full Text] [Related]

  • 23. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT.
    J Thorac Oncol; 2017 May 20; 12(5):872-877. PubMed ID: 28088512
    [Abstract] [Full Text] [Related]

  • 24. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z.
    Cancer Cytopathol; 2019 Jul 20; 127(7):447-457. PubMed ID: 31025831
    [Abstract] [Full Text] [Related]

  • 25. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Yang CY, Lin MW, Chang YL, Wu CT.
    Cancer Biomark; 2017 Dec 12; 21(1):211-220. PubMed ID: 29036791
    [Abstract] [Full Text] [Related]

  • 26. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.
    Liam CK, Yew CY, Pang YK, Wong CK, Poh ME, Tan JL, Soo CI, Loh TC, Chin KK, Munusamy V, Liam YS, Ibrahim NH.
    BMC Cancer; 2023 Jul 14; 23(1):659. PubMed ID: 37452277
    [Abstract] [Full Text] [Related]

  • 27. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H, Kwon HJ, Park SY, Park Y, Park E, Chung JH.
    PLoS One; 2018 Jul 14; 13(6):e0198634. PubMed ID: 29856861
    [Abstract] [Full Text] [Related]

  • 28. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
    Chang YL, Yang CY, Lin MW, Wu CT, Yang PC.
    Eur J Cancer; 2016 Jun 14; 60():125-35. PubMed ID: 27107327
    [Abstract] [Full Text] [Related]

  • 29. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z, Nart D, Savaş P, Veral A.
    Balkan Med J; 2021 Sep 14; 38(5):287-295. PubMed ID: 34558414
    [Abstract] [Full Text] [Related]

  • 30. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
    Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.
    Lung Cancer; 2018 Apr 14; 118():36-40. PubMed ID: 29572000
    [Abstract] [Full Text] [Related]

  • 31. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX, Ma N, Han J, He Z, Wang L, Wang Q.
    Zhonghua Yi Xue Za Zhi; 2022 Apr 05; 102(13):922-929. PubMed ID: 35385963
    [Abstract] [Full Text] [Related]

  • 32. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
    Guo J, Yuan H, Zhu Y, Che Z, Zhang B, Zhang D, Zhou Y, Xiong L.
    Medicine (Baltimore); 2024 Feb 23; 103(8):e36770. PubMed ID: 38394518
    [Abstract] [Full Text] [Related]

  • 33. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
    Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, Liu TT, Huang CC, Lin MC.
    Thorac Cancer; 2022 Jan 23; 13(1):38-47. PubMed ID: 34841687
    [Abstract] [Full Text] [Related]

  • 34. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
    Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J, Israel Lung Cancer Group.
    Oncoimmunology; 2021 Jan 28; 10(1):1865653. PubMed ID: 33552685
    [No Abstract] [Full Text] [Related]

  • 35. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL, Yang CY, Lin MW, Wu CT, Yang PC.
    Lung Cancer; 2015 Jun 28; 88(3):254-9. PubMed ID: 25862146
    [Abstract] [Full Text] [Related]

  • 36. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
    Zhao M, Zhan C, Li M, Yang X, Yang X, Zhang Y, Lin M, Xia Y, Feng M, Wang Q.
    J Thorac Dis; 2018 Jan 28; 10(1):398-407. PubMed ID: 29600072
    [Abstract] [Full Text] [Related]

  • 37. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    Zheng Q, Huang Y, Zeng X, Chen X, Shao S, Jin Y, Xue Q, Wang Y, Guo Y, Gu B, Wu C, Li Y.
    J Cancer Res Clin Oncol; 2021 May 28; 147(5):1547-1556. PubMed ID: 33196892
    [Abstract] [Full Text] [Related]

  • 38. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF, Chen XY, Yu XB.
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr 08; 45(4):221-5. PubMed ID: 27033383
    [Abstract] [Full Text] [Related]

  • 39. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M.
    Clin Cancer Res; 2016 Sep 15; 22(18):4585-93. PubMed ID: 27225694
    [Abstract] [Full Text] [Related]

  • 40. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
    Dang AH, Tran VU, Tran TT, Thi Pham HA, Le DT, Nguyen L, Nguyen NV, Thi Nguyen TH, Nguyen CV, Le HT, Thi Nguyen ML, Le VT, Nguyen PH, Vo BT, Thi Dao HT, Nguyen LT, Van Nguyen TC, Bui QN, Nguyen LH, Nguyen NH, Thi Nguyen QT, Le TX, Do TT, Dinh KT, Do HN, Phan MD, Nguyen HN, Tran LS, Giang H.
    Sci Rep; 2020 Feb 17; 10(1):2707. PubMed ID: 32066856
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.